In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genetic analysis specialist Sequenom nets $92mm in public offer

Executive Summary

Sequenom (platforms for genetic research and molecular diagnostics) netted $92mm through the follow-on public sale of 6.3mm shares (including the overallotment) at $15.50 each. The company will put the money towards developing noninvasive diagnostics that use its nucleic acid analysis system MassARRAY. Under a license from the Chinese University of Hong Kong, Sequenom is initially focusing on prenatal testing to identify fetal gene and chromosome abnormalities.
Deal Industry
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies